We are in COPD season, but it does not have to overwhelm the health system.

We are in COPD season, but it does not have to overwhelm the health system.

Experts are sounding the alarm about the “tripledemia” driven by a rebound in covid-19 cases accompanied by a particularly challenging flu season and an increase in RSV hospitalizations. As the weather turns colder, people living with chronic obstructive pulmonary disease (COPD), and those who care for them, must face a fourth risk in addition to … Read more

Cancer wellness center offers hundreds of free services

Cancer wellness center offers hundreds of free services

AKRON, Ohio — Meet Angela Whorton, or as everyone knows her, Angel. Gary Abrahamsen | News 5 Angela Whorton She is the type of person you fall in love with immediately after meeting her. She is also a mother, a wife, a special needs teacher at Akron’s I Promise School, and a cancer survivor. “I’m … Read more

Enzyme inhibition reduces cancer-related bone loss and the number of bone metastases

Enzyme inhibition reduces cancer-related bone loss and the number of bone metastases

In our bones, specialized cells called osteoblasts are responsible for building bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim and the Hamburg Eppendorf University Medical Center have now identified an enzyme that controls the activity of osteoblasts. An agent that inhibits the activity … Read more

Mount Sinai researchers find a new, safer treatment for serious side effects of bone marrow transplantation

Mount Sinai researchers find a new, safer treatment for serious side effects of bone marrow transplantation

Newswise—New York, NY (December 14, 2022)— Researchers at the Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than standard of care for a serious, and sometimes fatal, side effect of bone marrow transplantation in cancer patients. Results from a phase 2 clinical trial were presented at the American … Read more

GOSH Delivers First Baseline Edited Cell Therapy for Relapsed T-Cell Leukemia Patient

GOSH Delivers First Baseline Edited Cell Therapy for Relapsed T-Cell Leukemia Patient

A patient with relapsed T-cell leukemia was administered base-edited T cells in a world-first use of a base-edited cell therapy, in a ‘bench-to-bed’ collaboration between UCL and Great Ormond Street Hospital for Children (OMG). The patient, Alyssa, 13, from Leicester, was diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) in 2021. She received all current conventional … Read more

Targeted therapies and new drug combinations show promise for the treatment of multiple leukemias

Targeted therapies and new drug combinations show promise for the treatment of multiple leukemias

Researchers from the University of Texas MD Anderson Cancer Center present compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results for advancing the use of targeted and combination therapies novel therapies in multiple types of leukemia, including newly diagnosed, high-risk acute myeloid … Read more

New drug shows early potential to fight multiple myeloma

New drug shows early potential to fight multiple myeloma

A one-of-a-kind drug known as modakafusp alfa has shown early potential to fight multiple myeloma, a form of bone marrow cancer, in a study presented by researchers at the University of Pennsylvania Abramson Cancer Center at the American Society for 2022 Hematology. (ASH) Annual Meeting (Abstract 565). Of patients in the multicenter Phase I/II trial … Read more

New drug shows early potential to fight multiple myeloma

New drug shows early potential to fight multiple myeloma

A one-of-a-kind drug known as modakafusp alfa has shown early potential to fight multiple myeloma, a form of bone marrow cancer, in a study presented by researchers at the University of Pennsylvania Abramson Cancer Center at the American Society for 2022 Hematology. (ASH) Annual Meeting (Abstract 565). Of patients in the multicenter Phase I/II trial … Read more

Galecto Announces Upcoming Poster Presentation Detailing the Results of the Intermediate… | News

Galecto Announces Upcoming Poster Presentation Detailing the Results of the Intermediate… |  News

Interim evaluation of GB2064 in the Phase 2 myelofibrosis trial showed objective bone marrow involvement and reduced collagen fibrosis in four of five evaluable patients GB2064 is an oral inhibitor of the collagen cross-linking enzyme LOXL-2, which is linked to myelofibrosis BOSTON, Dec. 7, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology … Read more

How a biomarker test saved this Kentucky mother’s life

How a biomarker test saved this Kentucky mother’s life

Brittany Hawkins was diagnosed with stage IV lung cancer and given 3-6 months to live. Then a biomarker test led to a targeted treatment that changed everything. Share on PinterestBrittany Hawkins (left) with her husband (right). Image provided by Brittany Hawkins In 2021, Brittany Hawkins received a shocking diagnosis that changed her life. During April … Read more